Endpoints News
Endpoints reports Eli Lilly is building a case for its triple agonist beyond obesity, where a launch is expected next year, with sleep apnea next in line.
Recap by typeshit. Full story at Endpoints News.
A retrospective study in Cureus looks back at how well once-weekly semaglutide worked, and how safe it was, for teenagers with obesity.
Presented at Sleep Europe 2026, both trials found retatrutide lowered the apnea-hypopnea index more than placebo, including in people with type 2 diabetes.
Observational data link GLP-1 drugs to fewer cases of some cancers, but trials have yet to show they prevent cancer or help survival after a diagnosis.
BusinessWorld Online covers a Lilly weight loss drug still in clinical trials. Few details were given beyond the headline.
The actor says GLP-1 drugs can make sense with a doctor's advice, but in his view no drug can stand in for working out.
The Sunrise health expert says unregulated peptide use can put people in hospital, and in the worst cases leave them needing a new liver.
Loading…